INSM

INSMED Inc

Pharmaceutical Preparations · SIC 2834CIK 1104506Held by 8 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

$0.61B

Net Income FY2025

$(1.28B)

EPS (Basic, as reported)

$-6.42

Net Margin FY2025

-210.5%

ROE FY2025

-172.8%

Total Equity

$0.74B

Shares Out

218M

Business description

INSMED Inc — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2009–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itRevenue: 0 → 606

Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025

Revenue0010136164188245305364606

Cost of revenue00(2)(24)(40)(44)(55)(66)(86)(123)

Gross profit—07112——————

Research & development(123)(110)(145)(132)(181)(273)(398)(571)(598)(771)

Selling, general & administrative——————(266)(345)(461)(701)

General & administrative(51)(79)(168)(211)(204)(234)(266)(345)——

Total operating expenses(173)(189)(317)(347)(430)(564)(703)(1,015)(1,242)(1,853)

Operating income(173)(189)(307)(235)(265)(375)(457)(710)(878)(1,247)

Interest expense(3)(6)(25)(28)(30)(40)(26)(82)(85)(84)

Other income (expense), net001(1)0(3)(6)20(2)

Pre-tax income(176)(193)(324)(254)(293)(436)(480)(747)(910)(1,272)

Income tax expense000(1)(1)(2)(1)(3)(4)(5)

Net income(176)(193)(324)(254)(294)(435)(482)(750)(914)(1,277)

EPS — basic———($3.01)($3.01)($3.88)($3.91)($5.34)($5.57)($6.42)

EPS — diluted———($3.01)($3.01)($3.88)($3.91)($5.34)($5.57)($6.42)

Shares outstanding — basic (M)6267778598112123140164199

Shares outstanding — diluted (M)6267778598112123140164199

Showing the latest 10 of 17 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.